Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Veracyte, Inc. VCYT
$23.42
-$0.16 (-0.68%)
На 18:00, 12 мая 2023
+4.61%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1693114136.00000000
-
week52high
32.40
-
week52low
14.85
-
Revenue
296536000
-
P/E TTM
-46
-
Beta
1.40069200
-
EPS
-0.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 04 авг 2022 г. |
| Needham | Buy | Buy | 03 авг 2022 г. |
| Stephens & Co. | Overweight | Overweight | 05 мая 2022 г. |
| Raymond James | Outperform | Outperform | 04 мая 2022 г. |
| Needham | Buy | Buy | 04 мая 2022 г. |
| Raymond James | Outperform | Outperform | 04 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 03 ноя 2022 г. |
| Needham | Buy | Buy | 03 ноя 2022 г. |
| Morgan Stanley | Underweight | Underweight | 04 ноя 2022 г. |
| Scotiabank | Sector Outperform | 05 янв 2023 г. | |
| Raymond James | Market Perform | Outperform | 18 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Anderson Bonnie H | D | 102117 | 34000 | 17 янв 2023 г. |
| Anderson Bonnie H | D | 62961 | 4494 | 17 янв 2023 г. |
| Anderson Bonnie H | D | 67455 | 29506 | 17 янв 2023 г. |
| Anderson Bonnie H | A | 96961 | 34000 | 17 янв 2023 г. |
| Anderson Bonnie H | D | 26753 | 63247 | 11 янв 2023 г. |
| Anderson Bonnie H | D | 62961 | 63247 | 11 янв 2023 г. |
| Anderson Bonnie H | A | 126208 | 63247 | 11 янв 2023 г. |
| JONES EVAN/ FA | D | 50184 | 600 | 14 дек 2022 г. |
| JONES EVAN/ FA | D | 50784 | 300 | 13 дек 2022 г. |
| JONES EVAN/ FA | D | 51084 | 1367 | 13 дек 2022 г. |
Новостная лента
Veracyte, Inc. (VCYT) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 22:43
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc. Matt Sykes - Goldman Sachs Andrew Brackmann - William Blair Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2023 Financial Results Webcast.
Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
Zacks Investment Research
27 апр 2023 г. в 11:27
The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
Business Wire
13 апр 2023 г. в 17:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
7 Biotech Stocks That Could Be the Next Big Thing
InvestorPlace
15 мар 2023 г. в 11:44
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?
The Motley Fool
10 мар 2023 г. в 09:30
Veracyte's revenue grew at a healthy clip in the fourth quarter. The genomic test company's financial health looks solid.